|
TAF5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.24043006369357E-13 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62836411021772E-12 |
| Stage1-vs-Stage2 |
2.966800E-01 |
| Stage1-vs-Stage3 |
5.876300E-03 |
| Stage1-vs-Stage4 |
7.616100E-02 |
| Stage2-vs-Stage3 |
3.225200E-01 |
| Stage2-vs-Stage4 |
5.391600E-01 |
| Stage3-vs-Stage4 |
7.697200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
5.87100001947505E-09 |
| Normal-vs-Asian |
3.13170001042806E-09 |
| Caucasian-vs-AfricanAmerican |
8.690000E-01 |
| Caucasian-vs-Asian |
4.862200E-02 |
| AfricanAmerican-vs-Asian |
1.601410E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
1.215430E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(81-100Yrs) |
1.36459999999783E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.303900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.322790E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.813250E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.817400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.086800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.181000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.624200E-04 |
| Classical-VS-Follicular |
8.959600E-02 |
| Classical-VS-Other |
6.451800E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
5.084000E-02 |
| Tall-VS-Other |
2.392200E-01 |
| Tall-VS-Normal |
1.11022302462516E-16 |
| Follicular-VS-Other |
9.189800E-01 |
| Follicular-VS-Normal |
1.62447832963153E-12 |
| Other-VS-Normal |
2.816900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
6.99440505513849E-15 |
| N0-vs-N1 |
3.877600E-01 |
|
|
